Kiora Pharmaceuticals
KPRX
11 hedge funds and large institutions have $519K invested in Kiora Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
148% more capital invested
Capital invested by funds: $209K → $519K (+$310K)
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
22% more funds holding
Funds holding: 9 → 11 (+2)
0.52% more ownership
Funds ownership: 0.41% → 0.93% (+0.52%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
+$427K |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$169K |
| 3 |
BFM
Boothbay Fund Management
New York
|
+$59.8K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$21.9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$10.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$86K |
| 2 |
Morgan Stanley
New York
|
-$11.6K |
| 3 |
SFM
Spartan Fund Management
Toronto, Ontario,
Canada
|
-$6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Walleye Capital
New York
| $286K | +$427K | +9,256 | New |
|
|
WAM
2
Warberg Asset Management
Winnetka,
Illinois
| $113K | +$169K | +3,667 | New |
|
3
BlackRock
New York
| $49.6K | – | – | – |
|
|
BFM
4
Boothbay Fund Management
New York
| $40.1K | +$59.8K | +1,298 | New |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $15K | +$21.9K | +475 | New |
|
|
6
UBS Group
Zurich,
Switzerland
| $14.6K | +$10.8K | +235 | +99% |
|
|
7
Morgan Stanley
New York
| $397 | -$11.6K | -251 | -95% |
|
8
US Bancorp
Minneapolis,
Minnesota
| $230 | – | – | – |
|
9
Wells Fargo
San Francisco,
California
| $24 | – | – | – |
|
|
AFG
10
Albion Financial Group
Salt Lake City,
Utah
| $21 | – | – | – |
|
|
11
Geode Capital Management
Boston,
Massachusetts
| – | -$86K | -1,556 | Closed |
|
|
SFM
12
Spartan Fund Management
Toronto, Ontario,
Canada
| – | -$6K | -111 | Closed |
|
KPRX Hedge Fund Activity: Q4 2022 in Review
11 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q4 2022, worth a combined $519K — up 148% from $209K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new KPRX positions and 2 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Walleye Capital, opening a new position worth an estimated $427K. The largest seller was Geode Capital Management, exiting entirely with an estimated $86K sold.
- 11 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q4 2022, up from 9 in Q3 2022.
- Funds reported $519K of Kiora Pharmaceuticals stock for Q4 2022, up 148% quarter-over-quarter.
- 4 funds opened new Kiora Pharmaceuticals positions in Q4 2022 and 2 closed out, a net change of +2 holders.
- The largest Kiora Pharmaceuticals buyer in Q4 2022 was Walleye Capital, an estimated $427K added.
- The largest Kiora Pharmaceuticals seller in Q4 2022 was Geode Capital Management, an estimated $86K sold.
Based on aggregated 13F filings for Q4 2022.